Ann: Last patient assessment completed for SARTATE trial, page-26

So how did we get from, "It won't matter too much by the time this gets to market because the newer scanners..." (basically saying that there won't be a use for this product because the newer scanners will be at market) to "It's certainly not going to be a winner takes all type scenario.It's much more nuanced than that and there's space for everyone to play."?

The two statements seem a bit contradictory no?

And also...this is a thread on a diagnostic product for NETs - is there anyone running a trial using one of the newer scanners and an NET diagnostic agent?